Wikipedia

Catenin beta-1

(Redirected from CTNNB1)

Catenin beta-1, also known as β-catenin (beta-catenin), is a protein that in humans is encoded by the CTNNB1 gene.

CTNNB1
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesCTNNB1, CTNNB, MRD19, armadillo, catenin beta 1, EVR7, NEDSDV
External IDsOMIM: 116806; MGI: 88276; HomoloGene: 1434; GeneCards: CTNNB1; OMA:CTNNB1 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1499

12387

Ensembl

ENSG00000168036

ENSMUSG00000006932

UniProt

P35222

Q02248

RefSeq (mRNA)

NM_001098209
NM_001098210
NM_001904
NM_001330729

NM_001165902
NM_007614

RefSeq (protein)

NP_001091679
NP_001091680
NP_001317658
NP_001895

NP_001159374
NP_031640

Location (UCSC)Chr 3: 41.19 – 41.26 MbChr 9: 120.76 – 120.79 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

β-Catenin is a dual function protein, involved in regulation and coordination of cell–cell adhesion and gene transcription. In humans, the CTNNB1 protein is encoded by the CTNNB1 gene.[5][6] In Drosophila, the homologous protein is called armadillo. β-catenin is a subunit of the cadherin protein complex and acts as an intracellular signal transducer in the Wnt signaling pathway.[7][8][9] It is a member of the catenin protein family and homologous to γ-catenin, also known as plakoglobin. β-Catenin is widely expressed in many tissues. In cardiac muscle, β-catenin localizes to adherens junctions in intercalated disc structures, which are critical for electrical and mechanical coupling between adjacent cardiomyocytes.

Mutations and overexpression of β-catenin are associated with many cancers, including hepatocellular carcinoma, colorectal carcinoma, lung cancer, malignant breast tumors, ovarian and endometrial cancer.[10] Alterations in the localization and expression levels of β-catenin have been associated with various forms of heart disease, including dilated cardiomyopathy. β-Catenin is regulated and destroyed by the beta-catenin destruction complex, and in particular by the adenomatous polyposis coli (APC) protein, encoded by the tumour-suppressing APC gene. Therefore, genetic mutation of the APC gene is also strongly linked to cancers, and in particular colorectal cancer resulting from familial adenomatous polyposis (FAP).

Discovery

edit

β-Catenin was initially discovered in the early 1990s as a component of a mammalian cell adhesion complex: a protein responsible for cytoplasmatic anchoring of cadherins.[11] But very soon, it was realized that the Drosophila protein armadillo – implicated in mediating the morphogenic effects of Wingless/Wnt – is homologous to the mammalian β-catenin, not just in structure but also in function.[12] Thus, β-catenin became one of the first examples of moonlighting: a protein performing more than one radically different cellular function.

Structure

edit

Protein structure

edit

The core of β-catenin consists of several very characteristic repeats, each approximately 40 amino acids long. Termed armadillo repeats, all these elements fold together into a single, rigid protein domain with an elongated shape – called armadillo (ARM) domain. An average armadillo repeat is composed of three alpha helices. The first repeat of β-catenin (near the N-terminus) is slightly different from the others – as it has an elongated helix with a kink, formed by the fusion of helices 1 and 2.[13] Due to the complex shape of individual repeats, the whole ARM domain is not a straight rod: it possesses a slight curvature, so that an outer (convex) and an inner (concave) surface is formed. This inner surface serves as a ligand-binding site for the various interaction partners of the ARM domains.

 
The simplified structure of β-catenin.

The segments N-terminal and far C-terminal to the ARM domain do not adopt any structure in solution by themselves. Yet these intrinsically disordered regions play a crucial role in β-catenin function. The N-terminal disordered region contains a conserved short linear motif responsible for binding of TrCP1 (also known as β-TrCP) E3 ubiquitin ligase – but only when it is phosphorylated. Degradation of β-catenin is thus mediated by this N-terminal segment. The C-terminal region, on the other hand, is a strong transactivator when recruited onto DNA. This segment is not fully disordered: part of the C-terminal extension forms a stable helix that packs against the ARM domain, but may also engage separate binding partners.[14] This small structural element (HelixC) caps the C-terminal end of the ARM domain, shielding its hydrophobic residues. HelixC is not necessary for β-catenin to function in cell–cell adhesion. On the other hand, it is required for Wnt signaling: possibly to recruit various coactivators, such as 14-3-3zeta.[15] Yet its exact partners among the general transcription complexes are still incompletely understood, and they likely involve tissue-specific players.[16] Notably, the C-terminal segment of β-catenin can mimic the effects of the entire Wnt pathway if artificially fused to the DNA binding domain of LEF1 transcription factor.[17]

Plakoglobin (also called γ-catenin) has a strikingly similar architecture to that of β-catenin. Not only their ARM domains resemble each other in both architecture and ligand binding capacity, but the N-terminal β-TrCP-binding motif is also conserved in plakoglobin, implying common ancestry and shared regulation with β-catenin.[18] However, plakoglobin is a very weak transactivator when bound to DNA – this is probably caused by the divergence of their C-terminal sequences (plakoglobin appears to lack the transactivator motifs, and thus inhibits the Wnt pathway target genes instead of activating them).[19]

Partners binding to the armadillo domain

edit
 
Partners competing for the main binding site on the ARM domain of β-catenin. The auxiliary binding site is not shown.

As sketched above, the ARM domain of β-catenin acts as a platform to which specific linear motifs may bind. Located in structurally diverse partners, the β-catenin binding motifs are typically disordered on their own, and typically adopt a rigid structure upon ARM domain engagement – as seen for short linear motifs. However, β-catenin interacting motifs also have a number of peculiar characteristics. First, they might reach or even surpass the length of 30 amino acids in length, and contact the ARM domain on an excessively large surface area. Another unusual feature of these motifs is their frequently high degree of phosphorylation. Such Ser/Thr phosphorylation events greatly enhance the binding of many β-catenin associating motifs to the ARM domain.[20]

The structure of β-catenin in complex with the catenin binding domain of the transcriptional transactivation partner TCF provided the initial structural roadmap of how many binding partners of β-catenin may form interactions.[21] This structure demonstrated how the otherwise disordered N-terminus of TCF adapted what appeared to be a rigid conformation, with the binding motif spanning many beta-catenin repeats. Relatively strong charged interaction "hot spots" were defined (predicted, and later verified, to be conserved for the β-catenin/E-cadherin interaction), as well as hydrophobic regions deemed important in the overall mode of binding and as potential therapeutic small molecule inhibitor targets against certain cancer forms. Furthermore, following studies demonstrated another peculiar characteristic, plasticity in the binding of the TCF N-terminus to beta-catenin.[22][23]

Similarly, we find the familiar E-cadherin, whose cytoplasmatic tail contacts the ARM domain in the same canonical fashion.[24] The scaffold protein axin (two closely related paralogs, axin 1 and axin 2) contains a similar interaction motif on its long, disordered middle segment.[25] Although one molecule of axin only contains a single β-catenin recruitment motif, its partner the adenomatous polyposis coli (APC) protein contains 11 such motifs in tandem arrangement per protomer, thus capable to interact with several β-catenin molecules at once.[26] Since the surface of the ARM domain can typically accommodate only one peptide motif at any given time, all these proteins compete for the same cellular pool of β-catenin molecules. This competition is the key to understand how the Wnt signaling pathway works.

However, this "main" binding site on the ARM domain β-catenin is by no means the only one. The first helices of the ARM domain form an additional, special protein-protein interaction pocket: This can accommodate a helix-forming linear motif found in the coactivator BCL9 (or the closely related BCL9L) – an important protein involved in Wnt signaling.[27] Although the precise details are much less clear, it appears that the same site is used by alpha-catenin when β-catenin is localized to the adherens junctions.[28] Because this pocket is distinct from the ARM domain's "main" binding site, there is no competition between alpha-catenin and E-cadherin or between TCF1 and BCL9, respectively.[29] On the other hand, BCL9 and BCL9L must compete with α-catenin to access β-catenin molecules.[30]

Function

edit

Regulation of degradation through phosphorylation

edit

The cellular level of β-catenin is mostly controlled by its ubiquitination and proteosomal degradation. The E3 ubiquitin ligase TrCP1 (also known as β-TrCP) can recognize β-catenin as its substrate through a short linear motif on the disordered N-terminus. However, this motif (Asp-Ser-Gly-Ile-His-Ser) of β-catenin needs to be phosphorylated on the two serines in order to be capable to bind β-TrCP. Phosphorylation of the motif is performed by Glycogen Synthase Kinase 3 alpha and beta (GSK3α and GSK3β). GSK3s are constitutively active enzymes implicated in several important regulatory processes. There is one requirement, though: substrates of GSK3 need to be pre-phosphorylated four amino acids downstream (C-terminally) of the actual target site. Thus it also requires a "priming kinase" for its activities. In the case of β-catenin, the most important priming kinase is Casein Kinase I (CKI). Once a serine-threonine rich substrate has been "primed", GSK3 can "walk" across it from C-terminal to N-terminal direction, phosphorylating every 4th serine or threonine residues in a row. This process will result in dual phosphorylation of the aforementioned β-TrCP recognition motif as well.

The beta-catenin destruction complex

edit

For GSK3 to be a highly effective kinase on a substrate, pre-phosphorylation is not enough. There is one additional requirement: Similar to the mitogen-activated protein kinases (MAPKs), substrates need to associate with this enzyme through high-affinity docking motifs. β-Catenin contains no such motifs, but a special protein does: axin. What is more, its GSK3 docking motif is directly adjacent to a β-catenin binding motif.[25] This way, axin acts as a true scaffold protein, bringing an enzyme (GSK3) together with its substrate (β-catenin) into close physical proximity.

 
Simplified structure of the β-catenin destruction complex. Note the high proportion of intrinsically disordered segments in the axin and APC proteins.

But even axin does not act alone. Through its N-terminal regulator of G-protein signaling (RGS) domain, it recruits the adenomatous polyposis coli (APC) protein. APC is like a huge "Christmas tree": with a multitude of β-catenin binding motifs (one APC molecule alone possesses 11 such motifs [26]), it may collect as many β-catenin molecules as possible.[31] APC can interact with multiple axin molecules at the same time as it has three SAMP motifs (Ser-Ala-Met-Pro) to bind the RGS domains found in axin. In addition, axin also has the potential to oligomerize through its C-terminal DIX domain. The result is a huge, multimeric protein assembly dedicated to β-catenin phosphorylation. This complex is usually called the beta-catenin destruction complex, although it is distinct from the proteosome machinery actually responsible for β-catenin degradation.[32] It only marks β-catenin molecules for subsequent destruction.

Wnt signaling and the regulation of destruction

edit

In resting cells, axin molecules oligomerize with each other through their C-terminal DIX domains, which have two binding interfaces. Thus they can build linear oligomers or even polymers inside the cytoplasm of cells. DIX domains are unique: the only other proteins known to have a DIX domain are Dishevelled and DIXDC1. (The single Dsh protein of Drosophila corresponds to three paralogous genes, Dvl1, Dvl2 and Dvl3 in mammals.) Dsh associates with the cytoplasmic regions of Frizzled receptors with its PDZ and DEP domains. When a Wnt molecule binds to Frizzled, it induces a poorly known cascade of events, that result in the exposure of dishevelled's DIX domain and the creation of a perfect binding site for axin. Axin is then titrated away from its oligomeric assemblies – the β-catenin destruction complex – by Dsh.[33] Once bound to the receptor complex, axin will be rendered incompetent for β-catenin binding and GSK3 activity. Importantly, the cytoplasmic segments of the Frizzled-associated LRP5 and LRP6 proteins contain GSK3 pseudo-substrate sequences (Pro-Pro-Pro-Ser-Pro-x-Ser), appropriately "primed" (pre-phosphorylated) by CKI, as if it were a true substrate of GSK3. These false target sites greatly inhibit GSK3 activity in a competitive manner.[34] This way receptor-bound axin will abolish mediating the phosphorylation of β-catenin. Since β-catenin is no longer marked for destruction, but continues to be produced, its concentration will increase. Once β-catenin levels rise high enough to saturate all binding sites in the cytoplasm, it will also translocate into the nucleus. Upon engaging the transcription factors LEF1, TCF1, TCF2 or TCF3, β-catenin forces them to disengage their previous partners: Groucho proteins. Unlike Groucho, that recruit transcriptional repressors (e.g. histone-lysine methyltransferases), β-catenin will bind transcriptional activators, switching on target genes.

Role in cell–cell adhesion

edit
 
The moonlighting of β-catenin.

Cell–cell adhesion complexes are essential for the formation of complex animal tissues. β-catenin is part of a protein complex that form adherens junctions.[35] These cell–cell adhesion complexes are necessary for the creation and maintenance of epithelial cell layers and barriers. As a component of the complex, β-catenin can regulate cell growth and adhesion between cells. It may also be responsible for transmitting the contact inhibition signal that causes cells to stop dividing once the epithelial sheet is complete.[36] The E-cadherin – β-catenin – α-catenin complex is weakly associated to actin filaments. Adherens junctions require significant protein dynamics in order to link to the actin cytoskeleton,[35] thereby enabling mechanotransduction.[37][38]

An important component of the adherens junctions are the cadherin proteins. Cadherins form the cell–cell junctional structures known as adherens junctions as well as the desmosomes. Cadherins are capable of homophilic interactions through their extracellular cadherin repeat domains, in a Ca2 -dependent manner; this can hold adjacent epithelial cells together. While in the adherens junction, cadherins recruit β-catenin molecules onto their intracellular regions[clarification needed]. β-catenin, in turn, associates with another highly dynamic protein, α-catenin, which directly binds to the actin filaments.[39] This is possible because α-catenin and cadherins bind at distinct sites to β-catenin.[40] The β-catenin – α-catenin complex can thus physically form a bridge between cadherins and the actin cytoskeleton.[41] Organization of the cadherin–catenin complex is additionally regulated through phosphorylation and endocytosis of its components.[citation needed]

Roles in development

edit

β-Catenin has a central role in directing several developmental processes, as it can directly bind transcription factors and be regulated by a diffusible extracellular substance: Wnt. It acts upon early embryos to induce entire body regions, as well as individual cells in later stages of development. It also regulates physiological regeneration processes.

Early embryonic patterning

edit

Wnt signaling and β-catenin dependent gene expression plays a critical role during the formation of different body regions in the early embryo. Experimentally modified embryos that do not express this protein will fail to develop mesoderm and initiate gastrulation.[42] Early embryos endomesoderm specification also involves the activation of the β-catenin dependent transcripional activity by the first morphogenetic movements of embryogenesis, though mechanotransduction processes. This feature being shared by vertebrate and arthropod bilateria, and by cnidaria, it was proposed to have been evolutionary inherited from its possible involvement in the endomesoderm specification of first metazoa.[43][44][45]

During the blastula and gastrula stages, Wnt as well as BMP and FGF pathways will induce the antero-posterior axis formation, regulate the precise placement of the primitive streak (gastrulation and mesoderm formation) as well as the process of neurulation (central nervous system development).[46]

In Xenopus oocytes, β-catenin is initially equally localized to all regions of the egg, but it is targeted for ubiquitination and degradation by the β-catenin destruction complex. Fertilization of the egg causes a rotation of the outer cortical layers, moving clusters of the Frizzled and Dsh proteins closer to the equatorial region. β-catenin will be enriched locally under the influence of Wnt signaling pathway in the cells that inherit this portion of the cytoplasm. It will eventually translocate to the nucleus to bind TCF3 in order to activate several genes that induce dorsal cell characteristics.[47] This signaling results in a region of cells known as the grey crescent, which is a classical organizer of embryonic development. If this region is surgically removed from the embryo, gastrulation does not occur at all. β-Catenin also plays a crucial role in the induction of the blastopore lip, which in turn initiates gastrulation.[48] Inhibition of GSK-3 translation by injection of antisense mRNA may cause a second blastopore and a superfluous body axis to form. A similar effect can result from the overexpression of β-catenin.[49]

Asymmetric cell division

edit

β-catenin has also been implicated in regulation of cell fates through asymmetric cell division in the model organism C. elegans. Similarly to the Xenopus oocytes, this is essentially the result of non-equal distribution of Dsh, Frizzled, axin and APC in the cytoplasm of the mother cell.[50]

Stem cell renewal

edit

One of the most important results of Wnt signaling and the elevated level of β-catenin in certain cell types is the maintenance of pluripotency.[46] The rate of stem cells in the colon is for instance ensured by such accumulation of β-catenin, which can be stimulated by the Wnt pathway.[51] High frequency peristaltic mechanical strains of the colon are also involved in the β-catenin dependent maintenance of homeostatic levels of colonic stem cells through processes of mechanotransduction. This feature is pathologically enhanced towards tumorigenic hyperproliferation in healthy cells compressed by pressure due genetically altered hyperproliferative tumorous cells.[52]

In other cell types and developmental stages, β-catenin may promote differentiation, especially towards mesodermal cell lineages.

Epithelial-to-mesenchymal transition

edit

β-Catenin also acts as a morphogen in later stages of embryonic development. Together with TGF-β, an important role of β-catenin is to induce a morphogenic change in epithelial cells. It induces them to abandon their tight adhesion and assume a more mobile and loosely associated mesenchymal phenotype. During this process, epithelial cells lose expression of proteins like E-cadherin, Zonula occludens 1 (ZO1), and cytokeratin. At the same time they turn on the expression of vimentin, alpha smooth muscle actin (ACTA2), and fibroblast-specific protein 1 (FSP1). They also produce extracellular matrix components, such as type I collagen and fibronectin. Aberrant activation of the Wnt pathway has been implicated in pathological processes such as fibrosis and cancer.[53] In cardiac muscle development, β-catenin performs a biphasic role. Initially, the activation of Wnt/β-catenin is essential for committing mesenchymal cells to a cardiac lineage; however, in later stages of development, the downregulation of β-catenin is required.[54][55][42]

Involvement in cardiac physiology

edit

In cardiac muscle, β-catenin forms a complex with N-cadherin at adherens junctions within intercalated disc structures, which are responsible for electrical and mechanical coupling of adjacent cardiac cells. Studies in a model of adult rat ventricular cardiomyocytes have shown that the appearance and distribution of β-catenin is spatio-temporally regulated during the redifferentiation of these cells in culture. Specifically, β-catenin is part of a distinct complex with N-cadherin and alpha-catenin, which is abundant at adherens junctions in early stages following cardiomyocyte isolation for the reformation of cell–cell contacts.[56] It has been shown that β-catenin forms a complex with emerin in cardiomyocytes at adherens junctions within intercalated discs; and this interaction is dependent on the presence of GSK 3-beta phosphorylation sites on β-catenin. Knocking out emerin significantly altered β-catenin localization and the overall intercalated disc architecture, which resembled a dilated cardiomyopathy phenotype.[57]

In animal models of cardiac disease, functions of β-catenin have been unveiled. In a guinea pig model of aortic stenosis and left ventricular hypertrophy, β-catenin was shown to change subcellular localization from intercalated discs to the cytosol, despite no change in the overall cellular abundance of β-catenin. vinculin showed a similar profile of change. N-cadherin showed no change, and there was no compensatory upregulation of plakoglobin at intercalated discs in the absence of β-catenin.[58] In a hamster model of cardiomyopathy and heart failure, cell–cell adhesions were irregular and disorganized, and expression levels of adherens junction/intercalated disc and nuclear pools of β-catenin were decreased.[59] These data suggest that a loss of β-catenin may play a role in the diseased intercalated discs that have been associated with cardiac muscle hypertrophy and heart failure. In a rat model of myocardial infarction, adenoviral gene transfer of nonphosphorylatable, constitutively-active β-catenin decreased MI size, activated the cell cycle, and reduced the amount of apoptosis in cardiomyocytes and cardiac myofibroblasts. This finding was coordinate with enhanced expression of pro-survival proteins, survivin and Bcl-2, and vascular endothelial growth factor while promoting the differentiation of cardiac fibroblasts into myofibroblasts. These findings suggest that β-catenin can promote the regeneration and healing process following myocardial infarction.[60] In a spontaneously-hypertensive heart failure rat model, investigators detected a shuttling of β-catenin from the intercalated disc/sarcolemma to the nucleus, evidenced by a reduction of β-catenin expression in the membrane protein fraction and an increase in the nuclear fraction. Additionally, they found a weakening in the association between glycogen synthase kinase-3β and β-catenin, which may indicate altered protein stability. Overall, results suggest that an enhanced nuclear localization of β-catenin may be important in the progression of cardiac hypertrophy.[61]

Regarding the mechanistic role of β-catenin in cardiac hypertrophy, transgenic mouse studies have shown somewhat conflicting results regarding whether upregulation of β-catenin is beneficial or detrimental.[62][63][64] A recent study using a conditional knockout mouse that either lacked β-catenin altogether or expressed a non-degradable form of β-catenin in cardiomyocytes reconciled a potential reason for these discrepancies. There appears to be strict control over the subcellular localization of β-catenin in cardiac muscle. Mice lacking β-catenin had no overt phenotype in the left ventricular myocardium; however, mice harboring a stabilized form of β-catenin developed dilated cardiomyopathy, suggesting that the temporal regulation of β-catenin by protein degradation mechanisms is critical for normal functioning of β-catenin in cardiac cells.[65] In a mouse model harboring knockout of a desmosomal protein, plakoglobin, implicated in arrhythmogenic right ventricular cardiomyopathy, the stabilization of β-catenin was also enhanced, presumably to compensate for the loss of its plakoglobin homolog. These changes were coordinate with Akt activation and glycogen synthase kinase 3β inhibition, suggesting once again that the abnormal stabilization of β-catenin may be involved in the development of cardiomyopathy.[66] Further studies employing a double knockout of plakoglobin and β-catenin showed that the double knockout developed cardiomyopathy, fibrosis and arrhythmias resulting in sudden cardiac death. Intercalated disc architecture was severely impaired and connexin 43-resident gap junctions were markedly reduced. Electrocardiogram measurements captured spontaneous lethal ventricular arrhythmias in the double transgenic animals, suggesting that the two catenins—β-catenin and plakoglobin—are critical and indispensable for mechanoelectrical coupling in cardiomyocytes.[67]

Clinical significance

edit

Role in depression

edit

Whether or not a given individual's brain can deal effectively with stress, and thus their susceptibility to depression, depends on the β-catenin in each person's brain, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published November 12, 2014, in the journal Nature.[68] Higher β-catenin signaling increases behavioral flexibility, whereas defective β-catenin signaling leads to depression and reduced stress management.[68]

Role in cardiac disease

edit

Altered expression profiles in β-catenin have been associated with dilated cardiomyopathy in humans. β-Catenin upregulation of expression has generally been observed in patients with dilated cardiomyopathy.[69] In a particular study, patients with end-stage dilated cardiomyopathy showed almost doubled estrogen receptor alpha (ER-alpha) mRNA and protein levels, and the ER-alpha/beta-catenin interaction, present at intercalated discs of control, non-diseased human hearts was lost, suggesting that the loss of this interaction at the intercalated disc may play a role in the progression of heart failure.[70] Together with BCL9 and PYGO proteins, β-catenin coordinates different aspects of heard development, and mutations in Bcl9 or Pygo in model organisms - such as the mouse and zebrafish - cause phenotypes that are very similar to human congenital heart disorders.[71]

Involvement in cancer

edit
 
β-Catenin level regulation and cancer.

β-Catenin is a proto-oncogene. Mutations of this gene are commonly found in a variety of cancers: in primary hepatocellular carcinoma, colorectal cancer, ovarian carcinoma, breast cancer, lung cancer and glioblastoma. It has been estimated that approximately 10% of all tissue samples sequenced from all cancers display mutations in the CTNNB1 gene.[72] Most of these mutations cluster on a tiny area of the N-terminal segment of β-catenin: the β-TrCP binding motif. Loss-of-function mutations of this motif essentially make ubiquitinylation and degradation of β-catenin impossible. It will cause β-catenin to translocate to the nucleus without any external stimulus and continuously drive transcription of its target genes. Increased nuclear β-catenin levels have also been noted in basal cell carcinoma (BCC),[73] head and neck squamous cell carcinoma (HNSCC), prostate cancer (CaP),[74] pilomatrixoma (PTR)[75] and medulloblastoma (MDB)[76] These observations may or may not implicate a mutation in the β-catenin gene: other Wnt pathway components can also be faulty.

 
β-catenin immunohistochemistry in solid pseudopapillary tumor, staining the nuclei in 98% of such cases.[77] Cytoplasm is also staining in this case.
 
Immunohistochemistry for β-catenin in uterine leiomyoma, which is negative as there is only staining of cytoplasm but not of cell nuclei. This is a consistent finding, which helps in distinguishing such tumors from β-catenin positive spindle cell tumors.[78]
 
Likewise, negative nuclear staining is seen in approximately 95% of gastrointestinal stromal tumors.[79].

Similar mutations are also frequently seen in the β-catenin recruiting motifs of APC. Hereditary loss-of-function mutations of APC cause a condition known as familial adenomatous polyposis. Affected individuals develop hundreds of polyps in their large intestine. Most of these polyps are benign in nature, but they have the potential to transform into deadly cancer as time progresses. Somatic mutations of APC in colorectal cancer are also not uncommon.[80] β-Catenin and APC are among the key genes (together with others, like K-Ras and SMAD4) involved in colorectal cancer development. The potential of β-catenin to change the previously epithelial phenotype of affected cells into an invasive, mesenchyme-like type contributes greatly to metastasis formation.

As a therapeutic target

edit

Due to its involvement in cancer development, inhibition of β-catenin continues to receive significant attention. But the targeting of the binding site on its armadillo domain is not the simplest task, due to its extensive and relatively flat surface. However, for an efficient inhibition, binding to smaller "hotspots" of this surface is sufficient. This way, a "stapled" helical peptide derived from the natural β-catenin binding motif found in LEF1 was sufficient for the complete inhibition of β-catenin dependent transcription. Recently, several small-molecule compounds have also been developed to target the same, highly positively charged area of the ARM domain (CGP049090, PKF118-310, PKF115-584 and ZTM000990). In addition, β-catenin levels can also be influenced by targeting upstream components of the Wnt pathway as well as the β-catenin destruction complex.[81] The additional N-terminal binding pocket is also important for Wnt target gene activation (required for BCL9 recruitment). This site of the ARM domain can be pharmacologically targeted by carnosic acid, for example.[82] That "auxiliary" site is another attractive target for drug development.[83] Despite intensive preclinical research, no β-catenin inhibitors are available as therapeutic agents yet. However, its function can be further examined by siRNA knockdown based on an independent validation.[84] Another therapeutic approach for reducing β-catenin nuclear accumulation is via the inhibition of galectin-3.[85] The galectin-3 inhibitor GR-MD-02 is currently undergoing clinical trials in combination with the FDA-approved dose of ipilimumab in patients who have advanced melanoma.[86] The proteins BCL9 and BCL9L have been proposed as therapeutic targets for colorectal cancers which present hyper-activated Wnt signaling, because their deletion does not perturb normal homeostasis but strongly affects metastases behaviour.[87]

Role in fetal alcohol syndrome

edit

β-catenin destabilization by ethanol is one of two known pathways whereby alcohol exposure induces fetal alcohol syndrome (the other is ethanol-induced folate deficiency). Ethanol leads to β-catenin destabilization via a G-protein-dependent pathway, wherein activated Phospholipase Cβ hydrolyzes phosphatidylinositol-(4,5)-bisphosphate to diacylglycerol and inositol-(1,4,5)-trisphosphate. Soluble inositol-(1,4,5)-trisphosphate triggers calcium to be released from the endoplasmic reticulum. This sudden increase in cytoplasmic calcium activates Ca2 /calmodulin-dependent protein kinase (CaMKII). Activated CaMKII destabilizes β-catenin via a poorly characterized mechanism, but which likely involves β-catenin phosphorylation by CaMKII. The β-catenin transcriptional program (which is required for normal neural crest cell development) is thereby suppressed, resulting in premature neural crest cell apoptosis (cell death).[88]

Interactions

edit

β-Catenin has been shown to interact with:

See also

edit

References

edit
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000168036 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000006932 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Kraus C, Liehr T, Hülsken J, Behrens J, Birchmeier W, Grzeschik KH, Ballhausen WG (September 1994). "Localization of the human beta-catenin gene (CTNNB1) to 3p21: a region implicated in tumor development". Genomics. 23 (1): 272–274. doi:10.1006/geno.1994.1493. PMID 7829088.
  6. ^ MacDonald BT, Tamai K, He X (July 2009). "Wnt/beta-catenin signaling: components, mechanisms, and diseases". Developmental Cell. 17 (1): 9–26. doi:10.1016/j.devcel.2009.06.016. PMC 2861485. PMID 19619488.
  7. ^ Peifer M, Rauskolb C, Williams M, Riggleman B, Wieschaus E (April 1991). "The segment polarity gene armadillo interacts with the wingless signaling pathway in both embryonic and adult pattern formation". Development. 111 (4): 1029–1043. doi:10.1242/dev.111.4.1029. PMID 1879348.
  8. ^ Noordermeer J, Klingensmith J, Perrimon N, Nusse R (January 1994). "dishevelled and armadillo act in the wingless signalling pathway in Drosophila". Nature. 367 (6458): 80–83. Bibcode:1994Natur.367...80N. doi:10.1038/367080a0. PMID 7906389. S2CID 4275610.
  9. ^ Peifer M, Berg S, Reynolds AB (March 1994). "A repeating amino acid motif shared by proteins with diverse cellular roles". Cell. 76 (5): 789–791. doi:10.1016/0092-8674(94)90353-0. PMID 7907279. S2CID 26528190.
  10. ^ Morin PJ (December 1999). "beta-catenin signaling and cancer". BioEssays. 21 (12): 1021–1030. doi:10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P. PMID 10580987. S2CID 86240312.
  11. ^ McCrea PD, Turck CW, Gumbiner B (November 1991). "A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin". Science. 254 (5036): 1359–1361. Bibcode:1991Sci...254.1359M. doi:10.1126/science.1962194. PMID 1962194.
  12. ^ Kemler R (September 1993). "From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion". Trends in Genetics. 9 (9): 317–321. doi:10.1016/0168-9525(93)90250-l. PMID 8236461.
  13. ^ Gottardi CJ, Peifer M (March 2008). "Terminal regions of beta-catenin come into view". Structure. 16 (3): 336–338. doi:10.1016/j.str.2008.02.005. PMC 2329800. PMID 18334207.
  14. ^ Xing Y, Takemaru K, Liu J, Berndt JD, Zheng JJ, Moon RT, Xu W (March 2008). "Crystal structure of a full-length beta-catenin". Structure. 16 (3): 478–487. doi:10.1016/j.str.2007.12.021. PMC 4267759. PMID 18334222.
  15. ^ Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, et al. (April 2007). "Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity". The Journal of Biological Chemistry. 282 (15): 11221–11229. doi:10.1074/jbc.M611871200. PMC 1850976. PMID 17287208.
  16. ^ Söderholm S, Cantù C (May 2021). "The WNT/β-catenin dependent transcription: A tissue-specific business". WIREs Mechanisms of Disease. 13 (3): e1511. doi:10.1002/wsbm.1511. PMC 9288632. PMID 33085215.
  17. ^ Vleminckx K, Kemler R, Hecht A (March 1999). "The C-terminal transactivation domain of beta-catenin is necessary and sufficient for signaling by the LEF-1/beta-catenin complex in Xenopus laevis". Mechanisms of Development. 81 (1–2): 65–74. doi:10.1016/s0925-4773(98)00225-1. PMID 10330485. S2CID 15086656.
  18. ^ Sadot E, Simcha I, Iwai K, Ciechanover A, Geiger B, Ben-Ze'ev A (April 2000). "Differential interaction of plakoglobin and β-catenin with the ubiquitin-proteasome system". Oncogene. 19 (16): 1992–2001. doi:10.1038/sj.onc.1203519. PMID 10803460. S2CID 2872966.
  19. ^ Aktary Z, Pasdar M (2012). "Plakoglobin: role in tumorigenesis and metastasis". International Journal of Cell Biology. 2012: 189521. doi:10.1155/2012/189521. PMC 3312339. PMID 22481945.
  20. ^ Xu W, Kimelman D (October 2007). "Mechanistic insights from structural studies of β-catenin and its binding partners". Journal of Cell Science. 120 (Pt 19): 3337–3344. doi:10.1242/jcs.013771. PMID 17881495. S2CID 25294495.
  21. ^ Graham TA, Weaver C, Mao F, Kimelman D, Xu W (December 2000). "Crystal structure of a beta-catenin/Tcf complex". Cell. 103 (6): 885–896. doi:10.1016/S0092-8674(00)00192-6. PMID 11136974. S2CID 16865193.
  22. ^ Graham TA, Ferkey DM, Mao F, Kimelman D, Xu W (December 2001). "Tcf4 can specifically recognize beta-catenin using alternative conformations". Nature Structural Biology. 8 (12): 1048–1052. doi:10.1038/nsb718. PMID 11713475. S2CID 33878077.
  23. ^ Poy F, Lepourcelet M, Shivdasani RA, Eck MJ (December 2001). "Structure of a human Tcf4-beta-catenin complex". Nature Structural Biology. 8 (12): 1053–1057. doi:10.1038/nsb720. PMID 11713476. S2CID 24798619.
  24. ^ a b Huber AH, Weis WI (May 2001). "The structure of the beta-catenin/E-cadherin complex and the molecular basis of diverse ligand recognition by beta-catenin". Cell. 105 (3): 391–402. doi:10.1016/S0092-8674(01)00330-0. PMID 11348595. S2CID 364223.
  25. ^ a b Xing Y, Clements WK, Kimelman D, Xu W (November 2003). "Crystal structure of a beta-catenin/axin complex suggests a mechanism for the beta-catenin destruction complex". Genes & Development. 17 (22): 2753–2764. doi:10.1101/gad.1142603. PMC 280624. PMID 14600025.
  26. ^ a b Minde DP, Anvarian Z, Rüdiger SG, Maurice MM (August 2011). "Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer?". Molecular Cancer. 10 (1): 101. doi:10.1186/1476-4598-10-101. PMC 3170638. PMID 21886364.
  27. ^ Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, et al. (April 2002). "Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex". Cell. 109 (1): 47–60. doi:10.1016/S0092-8674(02)00679-7. PMID 11955446. S2CID 16720801.
  28. ^ Pokutta S, Weis WI (March 2000). "Structure of the dimerization and beta-catenin-binding region of alpha-catenin". Molecular Cell. 5 (3): 533–543. doi:10.1016/S1097-2765(00)80447-5. PMID 10882138.
  29. ^ Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W (October 2006). "Crystal structure of a beta-catenin/BCL9/Tcf4 complex". Molecular Cell. 24 (2): 293–300. doi:10.1016/j.molcel.2006.09.001. PMID 17052462.
  30. ^ Brembeck FH, Schwarz-Romond T, Bakkers J, Wilhelm S, Hammerschmidt M, Birchmeier W (September 2004). "Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions". Genes & Development. 18 (18): 2225–2230. doi:10.1101/gad.317604. PMC 517514. PMID 15371335.
  31. ^ Liu J, Xing Y, Hinds TR, Zheng J, Xu W (June 2006). "The third 20 amino acid repeat is the tightest binding site of APC for beta-catenin". Journal of Molecular Biology. 360 (1): 133–144. doi:10.1016/j.jmb.2006.04.064. PMID 16753179.
  32. ^ Kimelman D, Xu W (December 2006). "beta-catenin destruction complex: insights and questions from a structural perspective". Oncogene. 25 (57): 7482–7491. doi:10.1038/sj.onc.1210055. PMID 17143292. S2CID 20529520.
  33. ^ Fiedler M, Mendoza-Topaz C, Rutherford TJ, Mieszczanek J, Bienz M (February 2011). "Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin". Proceedings of the National Academy of Sciences of the United States of America. 108 (5): 1937–1942. Bibcode:2011PNAS..108.1937F. doi:10.1073/pnas.1017063108. PMC 3033301. PMID 21245303.
  34. ^ Metcalfe C, Bienz M (November 2011). "Inhibition of GSK3 by Wnt signalling--two contrasting models". Journal of Cell Science. 124 (Pt 21): 3537–3544. doi:10.1242/jcs.091991. PMID 22083140.
  35. ^ a b Brembeck FH, Rosário M, Birchmeier W (February 2006). "Balancing cell adhesion and Wnt signaling, the key role of beta-catenin". Current Opinion in Genetics & Development. 16 (1): 51–59. doi:10.1016/j.gde.2005.12.007. PMID 16377174.
  36. ^ "Entrez Gene: catenin (cadherin-associated protein)".
  37. ^ Bush M, Alhanshali BM, Qian S, Stanley CB, Heller WT, Matsui T, et al. (October 2019). "An ensemble of flexible conformations underlies mechanotransduction by the cadherin-catenin adhesion complex". Proceedings of the National Academy of Sciences of the United States of America. 116 (43): 21545–21555. Bibcode:2019PNAS..11621545B. doi:10.1073/pnas.1911489116. PMC 6815173. PMID 31591245.
  38. ^ Röper JC, Mitrossilis D, Stirnemann G, Waharte F, Brito I, Fernandez-Sanchez ME, et al. (July 2018). "The major β-catenin/E-cadherin junctional binding site is a primary molecular mechano-transductor of differentiation in vivo". eLife. 7. doi:10.7554/eLife.33381. PMC 6053302. PMID 30024850.
  39. ^ Farago B, Nicholl ID, Wang S, Cheng X, Callaway DJ, Bu Z (March 2021). "Activated nanoscale actin-binding domain motion in the catenin-cadherin complex revealed by neutron spin echo spectroscopy". Proceedings of the National Academy of Sciences of the United States of America. 118 (13): e2025012118. Bibcode:2021PNAS..11825012F. doi:10.1073/pnas.2025012118. PMC 8020631. PMID 33753508.
  40. ^ Nelson WJ (April 2008). "Regulation of cell-cell adhesion by the cadherin-catenin complex". Biochemical Society Transactions. 36 (Pt 2): 149–155. doi:10.1042/BST0360149. PMC 3368607. PMID 18363555.
  41. ^ Bienz M (January 2005). "beta-Catenin: a pivot between cell adhesion and Wnt signalling". Current Biology. 15 (2): R64–R67. Bibcode:2005CBio...15..R64B. doi:10.1016/j.cub.2004.12.058. PMID 15668160. S2CID 12352182.
  42. ^ a b Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, Kemler R (November 1995). "Lack of beta-catenin affects mouse development at gastrulation". Development. 121 (11): 3529–3537. doi:10.1242/dev.121.11.3529. PMID 8582267.
  43. ^ Farge E (2003). "Mechanical induction of twist in the Drosophila foregut/stomodeal primordium". Current Biology. 13 (16): 1365–1377. Bibcode:2003CBio...13.1365F. doi:10.1016/s0960-9822(03)00576-1. PMID 1293230.
  44. ^ Brunet T, Bouclet A, Ahmadi P, Mitrossilis D, Driquez B, Brunet AC, et al. (2013). "Evolutionary conservation of early mesoderm specification by mechanotransduction in Bilateria". Nature Communications. 4: 2821. Bibcode:2013NatCo...4.2821B. doi:10.1038/ncomms3821. PMC 3868206. PMID 24281726.
  45. ^ Nguyen NM, Merle T, Broders-Bondon F, Brunet AC, Battistella A, Land EB, et al. (2022). "Mechano-biochemical marine stimulation of inversion, gastrulation, and endomesoderm specification in multicellular Eukaryota". Frontiers in Cell and Developmental Biology. 10: 992371. doi:10.3389/fcell.2022.992371. PMC 9754125. PMID 36531949.
  46. ^ a b Sokol SY (October 2011). "Maintaining embryonic stem cell pluripotency with Wnt signaling". Development. 138 (20): 4341–4350. doi:10.1242/dev.066209. PMC 3177306. PMID 21903672.
  47. ^ Schneider S, Steinbeisser H, Warga RM, Hausen P (July 1996). "Beta-catenin translocation into nuclei demarcates the dorsalizing centers in frog and fish embryos". Mechanisms of Development. 57 (2): 191–198. doi:10.1016/0925-4773(96)00546-1. PMID 8843396. S2CID 12694740.
  48. ^ Larabell CA, Torres M, Rowning BA, Yost C, Miller JR, Wu M, et al. (March 1997). "Establishment of the dorso-ventral axis in Xenopus embryos is presaged by early asymmetries in β-catenin that are modulated by the Wnt signaling pathway". The Journal of Cell Biology. 136 (5): 1123–1136. doi:10.1083/jcb.136.5.1123. PMC 2132470. PMID 9060476.
  49. ^ Kelly GM, Erezyilmaz DF, Moon RT (October 1995). "Induction of a secondary embryonic axis in zebrafish occurs following the overexpression of beta-catenin". Mechanisms of Development. 53 (2): 261–273. doi:10.1016/0925-4773(95)00442-4. PMID 8562427. S2CID 14885037.
  50. ^ Sawa H (2012). "Chapter 3: Control of cell polarity and asymmetric division in C. elegans". In Yang Y (ed.). Planar Cell Polarity During Development. Current Topics in Developmental Biology. Vol. 101. pp. 55–76. doi:10.1016/B978-0-12-394592-1.00003-X. ISBN 978-0-12-394592-1. PMID 23140625.
  51. ^ Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M, et al. (October 2007). "Identification of stem cells in small intestine and colon by marker gene Lgr5". Nature. 449 (7165): 1003–1007. Bibcode:2007Natur.449.1003B. doi:10.1038/nature06196. PMID 17934449. S2CID 4349637.
  52. ^ Nguyen Ho-Bouldoires TH, Sollier K, Zamfirov L, Broders-Bondon F, Mitrossilis D, Bermeo S, et al. (February 2022). "Ret kinase-mediated mechanical induction of colon stem cells by tumor growth pressure stimulates cancer progression in vivo". Communications Biology. 5 (1): 137. doi:10.1038/s42003-022-03079-4. PMC 8854631. PMID 35177769.
  53. ^ Tian X, Liu Z, Niu B, Zhang J, Tan TK, Lee SR, et al. (2011). "E-cadherin/β-catenin complex and the epithelial barrier". Journal of Biomedicine & Biotechnology. 2011: 567305. doi:10.1155/2011/567305. PMC 3191826. PMID 22007144.
  54. ^ Zelarayan L, Gehrke C, Bergmann MW (September 2007). "Role of beta-catenin in adult cardiac remodeling". Cell Cycle. 6 (17): 2120–2126. doi:10.4161/cc.6.17.4632. PMID 17786052.
  55. ^ Lickert H, Kutsch S, Kanzler B, Tamai Y, Taketo MM, Kemler R (August 2002). "Formation of multiple hearts in mice following deletion of beta-catenin in the embryonic endoderm". Developmental Cell. 3 (2): 171–181. doi:10.1016/s1534-5807(02)00206-x. PMID 12194849.
  56. ^ a b Hertig CM, Butz S, Koch S, Eppenberger-Eberhardt M, Kemler R, Eppenberger HM (January 1996). "N-cadherin in adult rat cardiomyocytes in culture. II. Spatio-temporal appearance of proteins involved in cell-cell contact and communication. Formation of two distinct N-cadherin/catenin complexes". Journal of Cell Science. 109 (1): 11–20. doi:10.1242/jcs.109.1.11. PMID 8834786.
  57. ^ Wheeler MA, Warley A, Roberts RG, Ehler E, Ellis JA (March 2010). "Identification of an emerin-beta-catenin complex in the heart important for intercalated disc architecture and beta-catenin localisation". Cellular and Molecular Life Sciences. 67 (5): 781–796. doi:10.1007/s00018-009-0219-8. PMC 11115513. PMID 19997769. S2CID 27205170.
  58. ^ Wang X, Gerdes AM (February 1999). "Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: III. Intercalated disc remodeling". Journal of Molecular and Cellular Cardiology. 31 (2): 333–343. doi:10.1006/jmcc.1998.0886. PMID 10093046.
  59. ^ Yoshida M, Ohkusa T, Nakashima T, Takanari H, Yano M, Takemura G, et al. (October 2011). "Alterations in adhesion junction precede gap junction remodelling during the development of heart failure in cardiomyopathic hamsters". Cardiovascular Research. 92 (1): 95–105. doi:10.1093/cvr/cvr182. PMID 21693625.
  60. ^ Hahn JY, Cho HJ, Bae JW, Yuk HS, Kim KI, Park KW, et al. (October 2006). "Beta-catenin overexpression reduces myocardial infarct size through differential effects on cardiomyocytes and cardiac fibroblasts". The Journal of Biological Chemistry. 281 (41): 30979–30989. doi:10.1074/jbc.M603916200. PMID 16920707.
  61. ^ Zheng Q, Chen P, Xu Z, Li F, Yi XP (October 2013). "Expression and redistribution of β-catenin in the cardiac myocytes of left ventricle of spontaneously hypertensive rat". Journal of Molecular Histology. 44 (5): 565–573. doi:10.1007/s10735-013-9507-6. PMID 23591738. S2CID 18997718.
  62. ^ Baurand A, Zelarayan L, Betney R, Gehrke C, Dunger S, Noack C, et al. (May 2007). "Beta-catenin downregulation is required for adaptive cardiac remodeling". Circulation Research. 100 (9): 1353–1362. doi:10.1161/01.RES.0000266605.63681.5a. PMID 17413044.
  63. ^ Chen X, Shevtsov SP, Hsich E, Cui L, Haq S, Aronovitz M, et al. (June 2006). "The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy". Molecular and Cellular Biology. 26 (12): 4462–4473. doi:10.1128/MCB.02157-05. PMC 1489123. PMID 16738313.
  64. ^ Haq S, Michael A, Andreucci M, Bhattacharya K, Dotto P, Walters B, et al. (April 2003). "Stabilization of beta-catenin by a Wnt-independent mechanism regulates cardiomyocyte growth". Proceedings of the National Academy of Sciences of the United States of America. 100 (8): 4610–4615. Bibcode:2003PNAS..100.4610H. doi:10.1073/pnas.0835895100. PMC 153603. PMID 12668767.
  65. ^ Hirschy A, Croquelois A, Perriard E, Schoenauer R, Agarkova I, Hoerstrup SP, et al. (September 2010). "Stabilised beta-catenin in postnatal ventricular myocardium leads to dilated cardiomyopathy and premature death" (PDF). Basic Research in Cardiology. 105 (5): 597–608. doi:10.1007/s00395-010-0101-8. PMID 20376467. S2CID 21789076.
  66. ^ Li J, Swope D, Raess N, Cheng L, Muller EJ, Radice GL (March 2011). "Cardiac tissue-restricted deletion of plakoglobin results in progressive cardiomyopathy and activation of {beta}-catenin signaling". Molecular and Cellular Biology. 31 (6): 1134–1144. doi:10.1128/MCB.01025-10. PMC 3067899. PMID 21245375.
  67. ^ Swope D, Cheng L, Gao E, Li J, Radice GL (March 2012). "Loss of cadherin-binding proteins β-catenin and plakoglobin in the heart leads to gap junction remodeling and arrhythmogenesis". Molecular and Cellular Biology. 32 (6): 1056–1067. doi:10.1128/MCB.06188-11. PMC 3295003. PMID 22252313.
  68. ^ a b Dias C, Feng J, Sun H, Shao NY, Mazei-Robison MS, Damez-Werno D, et al. (December 2014). "β-catenin mediates stress resilience through Dicer1/microRNA regulation". Nature. 516 (7529): 51–55. Bibcode:2014Natur.516...51D. doi:10.1038/nature13976. PMC 4257892. PMID 25383518.
  69. ^ Perriard JC, Hirschy A, Ehler E (January 2003). "Dilated cardiomyopathy: a disease of the intercalated disc?". Trends in Cardiovascular Medicine. 13 (1): 30–38. doi:10.1016/s1050-1738(02)00209-8. PMID 12554098.
  70. ^ a b Mahmoodzadeh S, Eder S, Nordmeyer J, Ehler E, Huber O, Martus P, et al. (May 2006). "Estrogen receptor alpha up-regulation and redistribution in human heart failure". FASEB Journal. 20 (7): 926–934. doi:10.1096/fj.05-5148com. PMID 16675850. S2CID 2246390.
  71. ^ Cantù C, Felker A, Zimmerli D, Prummel KD, Cabello EM, Chiavacci E, et al. (November 2018). "Mutations in Bcl9 and Pygo genes cause congenital heart defects by tissue-specific perturbation of Wnt/β-catenin signaling". Genes & Development. 32 (21–22): 1443–1458. doi:10.1101/gad.315531.118. PMC 6217730. PMID 30366904.
  72. ^ Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. (January 2011). "COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer". Nucleic Acids Research. 39 (Database issue): D945–D950. doi:10.1093/nar/gkq929. PMC 3013785. PMID 20952405.
  73. ^ Saldanha G, Ghura V, Potter L, Fletcher A (July 2004). "Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation". The British Journal of Dermatology. 151 (1): 157–164. doi:10.1111/j.1365-2133.2004.06048.x. PMID 15270885. S2CID 31114274.
  74. ^ Kypta RM, Waxman J (August 2012). "Wnt/β-catenin signalling in prostate cancer". Nature Reviews. Urology. 9 (8): 418–428. doi:10.1038/nrurol.2012.116. PMID 22710668. S2CID 22945223.
  75. ^ Hassanein AM, Glanz SM, Kessler HP, Eskin TA, Liu C (November 2003). "beta-Catenin is expressed aberrantly in tumors expressing shadow cells. Pilomatricoma, craniopharyngioma, and calcifying odontogenic cyst". American Journal of Clinical Pathology. 120 (5): 732–736. doi:10.1309/EALEG7LD6W7167PX. PMID 14608900.
  76. ^ Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, et al. (November 2005). "beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee". Journal of Clinical Oncology. 23 (31): 7951–7957. doi:10.1200/JCO.2005.01.5479. PMID 16258095.
  77. ^ Pooja Navale, M.D., Omid Savari, M.D., Joseph F. Tomashefski, Jr., M.D., Monika Vyas, M.D. "Solid pseudopapillary neoplasm". Pathology Outlines.{{cite web}}: CS1 maint: multiple names: authors list (link) Last author update: 4 March 2022
  78. ^ El Sabeh M, Saha SK, Afrin S, Islam MS, Borahay MA (2021). "Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities". Mol Cell Biochem. 476 (9): 3513–3536. doi:10.1007/s11010-021-04174-6. PMC 9235413. PMID 33999334.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  79. ^ Carlson JW, Fletcher CD (2007). "Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature". Histopathology. 51 (4): 509–14. doi:10.1111/j.1365-2559.2007.02794.x. PMID 17711447.
  80. ^ Kobayashi M, Honma T, Matsuda Y, Suzuki Y, Narisawa R, Ajioka Y, Asakura H (May 2000). "Nuclear translocation of beta-catenin in colorectal cancer". British Journal of Cancer. 82 (10): 1689–1693. doi:10.1054/bjoc.1999.1112. PMC 2374509. PMID 10817505.
  81. ^ Voronkov A, Krauss S (2013). "Wnt/beta-catenin signaling and small molecule inhibitors". Current Pharmaceutical Design. 19 (4): 634–664. doi:10.2174/1381612811306040634. PMC 3529405. PMID 23016862.
  82. ^ de la Roche M, Rutherford TJ, Gupta D, Veprintsev DB, Saxty B, Freund SM, Bienz M (February 2012). "An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid". Nature Communications. 3 (2): 680. Bibcode:2012NatCo...3..680D. doi:10.1038/ncomms1680. PMC 3293410. PMID 22353711.
  83. ^ Takada K, Zhu D, Bird GH, Sukhdeo K, Zhao JJ, Mani M, et al. (August 2012). "Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling". Science Translational Medicine. 4 (148): 148ra117. doi:10.1126/scitranslmed.3003808. PMC 3631420. PMID 22914623.
  84. ^ Munkácsy G, Sztupinszki Z, Herman P, Bán B, Pénzváltó Z, Szarvas N, Győrffy B (September 2016). "Validation of RNAi Silencing Efficiency Using Gene Array Data shows 18.5% Failure Rate across 429 Independent Experiments". Molecular Therapy. Nucleic Acids. 5 (9): e366. doi:10.1038/mtna.2016.66. PMC 5056990. PMID 27673562.
  85. ^ Cao Z, Hao Z, Xin M, Yu L, Wang L, Zhang Y, et al. (December 2018). "Endogenous and exogenous galectin-3 promote the adhesion of tumor cells with low expression of MUC1 to HUVECs through upregulation of N-cadherin and CD44". Laboratory Investigation; A Journal of Technical Methods and Pathology. 98 (12): 1642–1656. doi:10.1038/s41374-018-0119-3. PMID 30171204. S2CID 52139917.
  86. ^ Clinical trial number NCT02117362 for "Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma" at ClinicalTrials.gov
  87. ^ Moor AE, Anderle P, Cantù C, Rodriguez P, Wiedemann N, Baruthio F, et al. (December 2015). "BCL9/9L-β-catenin Signaling is Associated With Poor Outcome in Colorectal Cancer". eBioMedicine. 2 (12): 1932–1943. doi:10.1016/j.ebiom.2015.10.030. PMC 4703711. PMID 26844272.
  88. ^ Flentke GR, Garic A, Amberger E, Hernandez M, Smith SM (July 2011). "Calcium-mediated repression of β-catenin and its transcriptional signaling mediates neural crest cell death in an avian model of fetal alcohol syndrome". Birth Defects Research. Part A, Clinical and Molecular Teratology. 91 (7): 591–602. doi:10.1002/bdra.20833. PMC 4827605. PMID 21630427.
  89. ^ Su LK, Vogelstein B, Kinzler KW (December 1993). "Association of the APC tumor suppressor protein with catenins". Science. 262 (5140): 1734–1737. Bibcode:1993Sci...262.1734S. doi:10.1126/science.8259519. PMID 8259519.
  90. ^ a b c d Kucerová D, Sloncová E, Tuhácková Z, Vojtechová M, Sovová V (December 2001). "Expression and interaction of different catenins in colorectal carcinoma cells". International Journal of Molecular Medicine. 8 (6): 695–698. doi:10.3892/ijmm.8.6.695. PMID 11712088.
  91. ^ Tickenbrock L, Kössmeier K, Rehmann H, Herrmann C, Müller O (March 2003). "Differences between the interaction of beta-catenin with non-phosphorylated and single-mimicked phosphorylated 20-amino acid residue repeats of the APC protein". Journal of Molecular Biology. 327 (2): 359–367. doi:10.1016/S0022-2836(03)00144-X. PMID 12628243.
  92. ^ a b Davies G, Jiang WG, Mason MD (April 2001). "The interaction between beta-catenin, GSK3beta and APC after motogen induced cell-cell dissociation, and their involvement in signal transduction pathways in prostate cancer". International Journal of Oncology. 18 (4): 843–847. doi:10.3892/ijo.18.4.843. PMID 11251183.
  93. ^ Ryo A, Nakamura M, Wulf G, Liou YC, Lu KP (September 2001). "Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC". Nature Cell Biology. 3 (9): 793–801. doi:10.1038/ncb0901-793. PMID 11533658. S2CID 664553.
  94. ^ Homma MK, Li D, Krebs EG, Yuasa Y, Homma Y (April 2002). "Association and regulation of casein kinase 2 activity by adenomatous polyposis coli protein". Proceedings of the National Academy of Sciences of the United States of America. 99 (9): 5959–5964. Bibcode:2002PNAS...99.5959K. doi:10.1073/pnas.092143199. PMC 122884. PMID 11972058.
  95. ^ Satoh K, Yanai H, Senda T, Kohu K, Nakamura T, Okumura N, et al. (June 1997). "DAP-1, a novel protein that interacts with the guanylate kinase-like domains of hDLG and PSD-95". Genes to Cells. 2 (6): 415–424. doi:10.1046/j.1365-2443.1997.1310329.x. PMID 9286858. S2CID 8934092.
  96. ^ Eklof Spink K, Fridman SG, Weis WI (November 2001). "Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex". The EMBO Journal. 20 (22): 6203–6212. doi:10.1093/emboj/20.22.6203. PMC 125720. PMID 11707392.
  97. ^ Nakamura T, Hamada F, Ishidate T, Anai K, Kawahara K, Toyoshima K, Akiyama T (June 1998). "Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3beta and APC and reduces the beta-catenin level". Genes to Cells. 3 (6): 395–403. doi:10.1046/j.1365-2443.1998.00198.x. PMID 9734785. S2CID 10875463.
  98. ^ Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH (June 2003). "Regulation of the Wnt signaling pathway by disabled-2 (Dab2)". The EMBO Journal. 22 (12): 3084–3094. doi:10.1093/emboj/cdg286. PMC 162138. PMID 12805222.
  99. ^ Yang F, Li X, Sharma M, Sasaki CY, Longo DL, Lim B, Sun Z (March 2002). "Linking beta-catenin to androgen-signaling pathway". The Journal of Biological Chemistry. 277 (13): 11336–11344. doi:10.1074/jbc.M111962200. PMID 11792709.
  100. ^ Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP (October 2004). "Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells". Molecular Endocrinology. 18 (10): 2388–2401. doi:10.1210/me.2003-0436. PMID 15256534.
  101. ^ Song LN, Coghlan M, Gelmann EP (January 2004). "Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor". Molecular Endocrinology. 18 (1): 70–85. doi:10.1210/me.2003-0189. PMID 14593076.
  102. ^ Amir AL, Barua M, McKnight NC, Cheng S, Yuan X, Balk SP (August 2003). "A direct beta-catenin-independent interaction between androgen receptor and T cell factor 4". The Journal of Biological Chemistry. 278 (33): 30828–30834. doi:10.1074/jbc.M301208200. PMID 12799378.
  103. ^ a b Mulholland DJ, Read JT, Rennie PS, Cox ME, Nelson CC (August 2003). "Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis". Oncogene. 22 (36): 5602–5613. doi:10.1038/sj.onc.1206802. PMID 12944908. S2CID 9301471.
  104. ^ Pawlowski JE, Ertel JR, Allen MP, Xu M, Butler C, Wilson EM, Wierman ME (June 2002). "Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells". The Journal of Biological Chemistry. 277 (23): 20702–20710. doi:10.1074/jbc.M200545200. PMID 11916967.
  105. ^ Takemaru K, Yamaguchi S, Lee YS, Zhang Y, Carthew RW, Moon RT (April 2003). "Chibby, a nuclear beta-catenin-associated antagonist of the Wnt/Wingless pathway". Nature. 422 (6934): 905–909. Bibcode:2003Natur.422..905T. doi:10.1038/nature01570. PMID 12712206. S2CID 4418716.
  106. ^ Davies G, Jiang WG, Mason MD (April 2001). "HGF/SF modifies the interaction between its receptor c-Met, and the E-cadherin/catenin complex in prostate cancer cells". International Journal of Molecular Medicine. 7 (4): 385–388. doi:10.3892/ijmm.7.4.385. PMID 11254878.
  107. ^ a b Oyama T, Kanai Y, Ochiai A, Akimoto S, Oda T, Yanagihara K, et al. (December 1994). "A truncated beta-catenin disrupts the interaction between E-cadherin and alpha-catenin: a cause of loss of intercellular adhesiveness in human cancer cell lines". Cancer Research. 54 (23): 6282–6287. PMID 7954478.
  108. ^ Hazan RB, Kang L, Roe S, Borgen PI, Rimm DL (December 1997). "Vinculin is associated with the E-cadherin adhesion complex". The Journal of Biological Chemistry. 272 (51): 32448–32453. doi:10.1074/jbc.272.51.32448. PMID 9405455.
  109. ^ Kinch MS, Clark GJ, Der CJ, Burridge K (July 1995). "Tyrosine phosphorylation regulates the adhesions of ras-transformed breast epithelia". The Journal of Cell Biology. 130 (2): 461–471. doi:10.1083/jcb.130.2.461. PMC 2199929. PMID 7542250.
  110. ^ Jiang MC, Liao CF, Tai CC (June 2002). "CAS/CSE 1 stimulates E-cadhrin-dependent cell polarity in HT-29 human colon epithelial cells". Biochemical and Biophysical Research Communications. 294 (4): 900–905. doi:10.1016/S0006-291X(02)00551-X. PMID 12061792.
  111. ^ a b c d Hazan RB, Norton L (April 1998). "The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton". The Journal of Biological Chemistry. 273 (15): 9078–9084. doi:10.1074/jbc.273.15.9078. PMID 9535896.
  112. ^ a b c Bonvini P, An WG, Rosolen A, Nguyen P, Trepel J, Garcia de Herreros A, et al. (February 2001). "Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription". Cancer Research. 61 (4): 1671–1677. PMID 11245482.
  113. ^ a b Li Y, Bharti A, Chen D, Gong J, Kufe D (December 1998). "Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and Cellular Biology. 18 (12): 7216–7224. doi:10.1128/mcb.18.12.7216. PMC 109303. PMID 9819408.
  114. ^ Wendeler MW, Praus M, Jung R, Hecking M, Metzig C, Gessner R (April 2004). "Ksp-cadherin is a functional cell-cell adhesion molecule related to LI-cadherin". Experimental Cell Research. 294 (2): 345–355. doi:10.1016/j.yexcr.2003.11.022. PMID 15023525.
  115. ^ a b Shibata T, Chuma M, Kokubu A, Sakamoto M, Hirohashi S (July 2003). "EBP50, a beta-catenin-associating protein, enhances Wnt signaling and is over-expressed in hepatocellular carcinoma". Hepatology. 38 (1): 178–186. doi:10.1053/jhep.2003.50270. PMID 12830000. S2CID 10325091.
  116. ^ a b Piedra J, Miravet S, Castaño J, Pálmer HG, Heisterkamp N, García de Herreros A, Duñach M (April 2003). "p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction". Molecular and Cellular Biology. 23 (7): 2287–2297. doi:10.1128/MCB.23.7.2287-2297.2003. PMC 150740. PMID 12640114.
  117. ^ Kang JS, Feinleib JL, Knox S, Ketteringham MA, Krauss RS (April 2003). "Promyogenic members of the Ig and cadherin families associate to positively regulate differentiation". Proceedings of the National Academy of Sciences of the United States of America. 100 (7): 3989–3994. Bibcode:2003PNAS..100.3989K. doi:10.1073/pnas.0736565100. PMC 153035. PMID 12634428.
  118. ^ Oneyama C, Nakano H, Sharma SV (March 2002). "UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug". Oncogene. 21 (13): 2037–2050. doi:10.1038/sj.onc.1205271. PMID 11960376. S2CID 23869665.
  119. ^ Navarro P, Lozano E, Cano A (August 1993). "Expression of E- or P-cadherin is not sufficient to modify the morphology and the tumorigenic behavior of murine spindle carcinoma cells. Possible involvement of plakoglobin". Journal of Cell Science. 105 (4): 923–934. doi:10.1242/jcs.105.4.923. hdl:10261/78716. PMID 8227214.
  120. ^ a b Takahashi K, Suzuki K, Tsukatani Y (July 1997). "Induction of tyrosine phosphorylation and association of beta-catenin with EGF receptor upon tryptic digestion of quiescent cells at confluence". Oncogene. 15 (1): 71–78. doi:10.1038/sj.onc.1201160. PMID 9233779. S2CID 10127053.
  121. ^ a b Dobrosotskaya IY, James GL (April 2000). "MAGI-1 interacts with beta-catenin and is associated with cell-cell adhesion structures". Biochemical and Biophysical Research Communications. 270 (3): 903–909. doi:10.1006/bbrc.2000.2471. PMID 10772923.
  122. ^ Geng L, Burrow CR, Li HP, Wilson PD (December 2000). "Modification of the composition of polycystin-1 multiprotein complexes by calcium and tyrosine phosphorylation". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1535 (1): 21–35. doi:10.1016/S0925-4439(00)00079-X. PMID 11113628.
  123. ^ Shibamoto S, Hayakawa M, Takeuchi K, Hori T, Miyazawa K, Kitamura N, et al. (March 1995). "Association of p120, a tyrosine kinase substrate, with E-cadherin/catenin complexes". The Journal of Cell Biology. 128 (5): 949–957. doi:10.1083/jcb.128.5.949. PMC 2120395. PMID 7876318.
  124. ^ Rao RK, Basuroy S, Rao VU, Karnaky KJ, Gupta A (December 2002). "Tyrosine phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress". The Biochemical Journal. 368 (Pt 2): 471–481. doi:10.1042/BJ20011804. PMC 1222996. PMID 12169098.
  125. ^ a b Schmeiser K, Grand RJ (April 1999). "The fate of E- and P-cadherin during the early stages of apoptosis". Cell Death and Differentiation. 6 (4): 377–386. doi:10.1038/sj.cdd.4400504. PMID 10381631.
  126. ^ Pai R, Dunlap D, Qing J, Mohtashemi I, Hotzel K, French DM (July 2008). "Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling". Cancer Research. 68 (13): 5086–5095. doi:10.1158/0008-5472.CAN-07-2325. PMID 18593907.
  127. ^ Straub BK, Boda J, Kuhn C, Schnoelzer M, Korf U, Kempf T, et al. (December 2003). "A novel cell-cell junction system: the cortex adhaerens mosaic of lens fiber cells". Journal of Cell Science. 116 (Pt 24): 4985–4995. doi:10.1242/jcs.00815. PMID 14625392.
  128. ^ Wahl JK, Kim YJ, Cullen JM, Johnson KR, Wheelock MJ (May 2003). "N-cadherin-catenin complexes form prior to cleavage of the proregion and transport to the plasma membrane". The Journal of Biological Chemistry. 278 (19): 17269–17276. doi:10.1074/jbc.M211452200. PMID 12604612.
  129. ^ Klingelhöfer J, Troyanovsky RB, Laur OY, Troyanovsky S (August 2000). "Amino-terminal domain of classic cadherins determines the specificity of the adhesive interactions". Journal of Cell Science. 113 (16): 2829–2836. doi:10.1242/jcs.113.16.2829. PMID 10910767.
  130. ^ Kesavapany S, Lau KF, McLoughlin DM, Brownlees J, Ackerley S, Leigh PN, et al. (January 2001). "p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction". The European Journal of Neuroscience. 13 (2): 241–247. doi:10.1046/j.1460-9568.2001.01376.x. PMID 11168528.
  131. ^ a b Lamberti C, Lin KM, Yamamoto Y, Verma U, Verma IM, Byers S, Gaynor RB (November 2001). "Regulation of beta-catenin function by the IkappaB kinases". The Journal of Biological Chemistry. 276 (45): 42276–42286. doi:10.1074/jbc.M104227200. PMID 11527961.
  132. ^ Roe S, Koslov ER, Rimm DL (June 1998). "A mutation in alpha-catenin disrupts adhesion in clone A cells without perturbing its actin and beta-catenin binding activity". Cell Adhesion and Communication. 5 (4): 283–296. doi:10.3109/15419069809040298. PMID 9762469.
  133. ^ Aberle H, Butz S, Stappert J, Weissig H, Kemler R, Hoschuetzky H (December 1994). "Assembly of the cadherin-catenin complex in vitro with recombinant proteins". Journal of Cell Science. 107 (12): 3655–3663. doi:10.1242/jcs.107.12.3655. PMID 7706414.
  134. ^ Reuver SM, Garner CC (April 1998). "E-cadherin mediated cell adhesion recruits SAP97 into the cortical cytoskeleton". Journal of Cell Science. 111 (8): 1071–1080. doi:10.1242/jcs.111.8.1071. PMID 9512503.
  135. ^ a b Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ (June 2002). "ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas". The Journal of Biological Chemistry. 277 (25): 22692–22698. doi:10.1074/jbc.M201975200. PMID 11950845.
  136. ^ Cartegni L, di Barletta MR, Barresi R, Squarzoni S, Sabatelli P, Maraldi N, et al. (December 1997). "Heart-specific localization of emerin: new insights into Emery-Dreifuss muscular dystrophy". Human Molecular Genetics. 6 (13): 2257–2264. doi:10.1093/hmg/6.13.2257. PMID 9361031.
  137. ^ Markiewicz E, Tilgner K, Barker N, van de Wetering M, Clevers H, Dorobek M, et al. (July 2006). "The inner nuclear membrane protein emerin regulates beta-catenin activity by restricting its accumulation in the nucleus". The EMBO Journal. 25 (14): 3275–3285. doi:10.1038/sj.emboj.7601230. PMC 1523183. PMID 16858403.
  138. ^ Wei Y, Renard CA, Labalette C, Wu Y, Lévy L, Neuveut C, et al. (February 2003). "Identification of the LIM protein FHL2 as a coactivator of beta-catenin". The Journal of Biological Chemistry. 278 (7): 5188–5194. doi:10.1074/jbc.M207216200. PMID 12466281.
  139. ^ Kishida S, Yamamoto H, Hino S, Ikeda S, Kishida M, Kikuchi A (June 1999). "DIX domains of Dvl and axin are necessary for protein interactions and their ability to regulate beta-catenin stability". Molecular and Cellular Biology. 19 (6): 4414–4422. doi:10.1128/mcb.19.6.4414. PMC 104400. PMID 10330181.
  140. ^ Kanai Y, Ochiai A, Shibata T, Oyama T, Ushijima S, Akimoto S, Hirohashi S (March 1995). "c-erbB-2 gene product directly associates with beta-catenin and plakoglobin". Biochemical and Biophysical Research Communications. 208 (3): 1067–1072. doi:10.1006/bbrc.1995.1443. PMID 7702605.
  141. ^ a b Edlund S, Lee SY, Grimsby S, Zhang S, Aspenström P, Heldin CH, Landström M (February 2005). "Interaction between Smad7 and beta-catenin: importance for transforming growth factor beta-induced apoptosis". Molecular and Cellular Biology. 25 (4): 1475–1488. doi:10.1128/MCB.25.4.1475-1488.2005. PMC 548008. PMID 15684397.
  142. ^ Grueneberg DA, Pablo L, Hu KQ, August P, Weng Z, Papkoff J (June 2003). "A functional screen in human cells identifies UBF2 as an RNA polymerase II transcription factor that enhances the beta-catenin signaling pathway". Molecular and Cellular Biology. 23 (11): 3936–3950. doi:10.1128/MCB.23.11.3936-3950.2003. PMC 155208. PMID 12748295.
  143. ^ Behrens J, von Kries JP, Kühl M, Bruhn L, Wedlich D, Grosschedl R, Birchmeier W (August 1996). "Functional interaction of beta-catenin with the transcription factor LEF-1". Nature. 382 (6592): 638–642. Bibcode:1996Natur.382..638B. doi:10.1038/382638a0. PMID 8757136. S2CID 4369341.
  144. ^ Labbé E, Letamendia A, Attisano L (July 2000). "Association of Smads with lymphoid enhancer binding factor 1/T cell-specific factor mediates cooperative signaling by the transforming growth factor-beta and wnt pathways". Proceedings of the National Academy of Sciences of the United States of America. 97 (15): 8358–8363. Bibcode:2000PNAS...97.8358L. doi:10.1073/pnas.150152697. PMC 26952. PMID 10890911.
  145. ^ Barolo S, Posakony JW (May 2002). "Three habits of highly effective signaling pathways: principles of transcriptional control by developmental cell signaling". Genes & Development. 16 (10). Cold Spring Harbor Laboratory Press & The Genetics Society: 1167–1181. doi:10.1101/gad.976502. PMID 12023297. S2CID 14376483. p. 1170: In ... zebrafish, reporter transgenes containing the TOPFLASH promoter are expressed in certain Wnt-responsive cell types (...Dorsky et al. 2002).
  146. ^ Yamamoto M, Bharti A, Li Y, Kufe D (May 1997). "Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion". The Journal of Biological Chemistry. 272 (19): 12492–12494. doi:10.1074/jbc.272.19.12492. PMID 9139698.
  147. ^ Durum SK, Aiello FB (2003). "Interleukin-7 induces MUC1". Cancer Biology & Therapy. 2 (2): 194–195. doi:10.4161/cbt.2.2.351. PMID 12750562.
  148. ^ Schroeder JA, Adriance MC, Thompson MC, Camenisch TD, Gendler SJ (March 2003). "MUC1 alters beta-catenin-dependent tumor formation and promotes cellular invasion". Oncogene. 22 (9): 1324–1332. doi:10.1038/sj.onc.1206291. PMID 12618757. S2CID 25619311.
  149. ^ Li Y, Kuwahara H, Ren J, Wen G, Kufe D (March 2001). "The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin". The Journal of Biological Chemistry. 276 (9): 6061–6064. doi:10.1074/jbc.C000754200. PMID 11152665.
  150. ^ Ren J, Li Y, Kufe D (May 2002). "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling". The Journal of Biological Chemistry. 277 (20): 17616–17622. doi:10.1074/jbc.M200436200. PMID 11877440.
  151. ^ Li Y, Ren J, Yu W, Li Q, Kuwahara H, Yin L, et al. (September 2001). "The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin". The Journal of Biological Chemistry. 276 (38): 35239–35242. doi:10.1074/jbc.C100359200. PMID 11483589.
  152. ^ Kennell JA, O'Leary EE, Gummow BM, Hammer GD, MacDougald OA (August 2003). "T-cell factor 4N (TCF-4N), a novel isoform of mouse TCF-4, synergizes with beta-catenin to coactivate C/EBPalpha and steroidogenic factor 1 transcription factors". Molecular and Cellular Biology. 23 (15): 5366–5375. doi:10.1128/MCB.23.15.5366-5375.2003. PMC 165725. PMID 12861022.
  153. ^ Mizusaki H, Kawabe K, Mukai T, Ariyoshi E, Kasahara M, Yoshioka H, et al. (April 2003). "Dax-1 (dosage-sensitive sex reversal-adrenal hypoplasia congenita critical region on the X chromosome, gene 1) gene transcription is regulated by wnt4 in the female developing gonad". Molecular Endocrinology. 17 (4): 507–519. doi:10.1210/me.2002-0362. PMID 12554773.
  154. ^ Ge X, Jin Q, Zhang F, Yan T, Zhai Q (January 2009). "PCAF acetylates {beta}-catenin and improves its stability". Molecular Biology of the Cell. 20 (1): 419–427. doi:10.1091/mbc.E08-08-0792. PMC 2613091. PMID 18987336.
  155. ^ Behrens J (October 2008). "One hit, two outcomes for VHL-mediated tumorigenesis". Nature Cell Biology. 10 (10): 1127–1128. doi:10.1038/ncb1008-1127. PMID 18830218. S2CID 36184371.
  156. ^ Wadham C, Gamble JR, Vadas MA, Khew-Goodall Y (June 2003). "The protein tyrosine phosphatase Pez is a major phosphatase of adherens junctions and dephosphorylates beta-catenin". Molecular Biology of the Cell. 14 (6): 2520–2529. doi:10.1091/mbc.E02-09-0577. PMC 194899. PMID 12808048.
  157. ^ Aicher B, Lerch MM, Müller T, Schilling J, Ullrich A (August 1997). "Cellular redistribution of protein tyrosine phosphatases LAR and PTPsigma by inducible proteolytic processing". The Journal of Cell Biology. 138 (3): 681–696. doi:10.1083/jcb.138.3.681. PMC 2141638. PMID 9245795.
  158. ^ Fuchs M, Müller T, Lerch MM, Ullrich A (July 1996). "Association of human protein-tyrosine phosphatase kappa with members of the armadillo family". The Journal of Biological Chemistry. 271 (28): 16712–16719. doi:10.1074/jbc.271.28.16712. PMID 8663237.
  159. ^ Besco JA, Hooft van Huijsduijnen R, Frostholm A, Rotter A (October 2006). "Intracellular substrates of brain-enriched receptor protein tyrosine phosphatase rho (RPTPrho/PTPRT)". Brain Research. 1116 (1): 50–57. doi:10.1016/j.brainres.2006.07.122. PMID 16973135. S2CID 23343123.
  160. ^ Wang B, Kishihara K, Zhang D, Hara H, Nomoto K (February 1997). "Molecular cloning and characterization of a novel human receptor protein tyrosine phosphatase gene, hPTP-J: down-regulation of gene expression by PMA and calcium ionophore in Jurkat T lymphoma cells". Biochemical and Biophysical Research Communications. 231 (1): 77–81. doi:10.1006/bbrc.1997.6004. PMID 9070223.
  161. ^ Yan HX, He YQ, Dong H, Zhang P, Zeng JZ, Cao HF, et al. (December 2002). "Physical and functional interaction between receptor-like protein tyrosine phosphatase PCP-2 and beta-catenin". Biochemistry. 41 (52): 15854–15860. doi:10.1021/bi026095u. PMID 12501215.
  162. ^ He Y, Yan H, Dong H, Zhang P, Tang L, Qiu X, et al. (April 2005). "Structural basis of interaction between protein tyrosine phosphatase PCP-2 and beta-catenin". Science in China Series C: Life Sciences. 48 (2): 163–167. doi:10.1007/bf02879669. PMID 15986889. S2CID 20799629.
  163. ^ Tesco G, Kim TW, Diehlmann A, Beyreuther K, Tanzi RE (December 1998). "Abrogation of the presenilin 1/beta-catenin interaction and preservation of the heterodimeric presenilin 1 complex following caspase activation". The Journal of Biological Chemistry. 273 (51): 33909–33914. doi:10.1074/jbc.273.51.33909. PMID 9852041.
  164. ^ Kang DE, Soriano S, Frosch MP, Collins T, Naruse S, Sisodia SS, et al. (June 1999). "Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway". The Journal of Neuroscience. 19 (11): 4229–4237. doi:10.1523/JNEUROSCI.19-11-04229.1999. PMC 6782616. PMID 10341227.
  165. ^ Murayama M, Tanaka S, Palacino J, Murayama O, Honda T, Sun X, et al. (August 1998). "Direct association of presenilin-1 with beta-catenin". FEBS Letters. 433 (1–2): 73–77. doi:10.1016/S0014-5793(98)00886-2. PMID 9738936. S2CID 85416623.
  166. ^ Puppo F, Thomé V, Lhoumeau AC, Cibois M, Gangar A, Lembo F, et al. (January 2011). "Protein tyrosine kinase 7 has a conserved role in Wnt/β-catenin canonical signalling". EMBO Reports. 12 (1): 43–49. doi:10.1038/embor.2010.185. PMC 3024124. PMID 21132015.
  167. ^ Bauer A, Huber O, Kemler R (December 1998). "Pontin52, an interaction partner of beta-catenin, binds to the TATA box binding protein". Proceedings of the National Academy of Sciences of the United States of America. 95 (25): 14787–14792. Bibcode:1998PNAS...9514787B. doi:10.1073/pnas.95.25.14787. PMC 24527. PMID 9843967.
  168. ^ Barker N, Hurlstone A, Musisi H, Miles A, Bienz M, Clevers H (September 2001). "The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation". The EMBO Journal. 20 (17): 4935–4943. doi:10.1093/emboj/20.17.4935. PMC 125268. PMID 11532957.
  169. ^ Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K (December 1999). "The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin". Genes to Cells. 4 (12): 757–767. doi:10.1046/j.1365-2443.1999.00297.x. PMID 10620020. S2CID 85747886.
  170. ^ Lewalle JM, Bajou K, Desreux J, Mareel M, Dejana E, Noël A, Foidart JM (December 1997). "Alteration of interendothelial adherens junctions following tumor cell-endothelial cell interaction in vitro". Experimental Cell Research. 237 (2): 347–356. doi:10.1006/excr.1997.3799. hdl:2268/61990. PMID 9434630.
  171. ^ Shasby DM, Ries DR, Shasby SS, Winter MC (June 2002). "Histamine stimulates phosphorylation of adherens junction proteins and alters their link to vimentin". American Journal of Physiology. Lung Cellular and Molecular Physiology. 282 (6): L1330–L1338. CiteSeerX 10.1.1.1000.5266. doi:10.1152/ajplung.00329.2001. PMID 12003790.
  172. ^ Sinn HW, Balsamo J, Lilien J, Lin JJ (September 2002). "Localization of the novel Xin protein to the adherens junction complex in cardiac and skeletal muscle during development". Developmental Dynamics. 225 (1): 1–13. doi:10.1002/dvdy.10131. PMID 12203715. S2CID 23393425.

Further reading

edit
edit

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Catenin_beta-1&oldid=1254888177"